MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-04-2026
Aquestive Therapeutics Shares 2011-2026 | AQST
Annual Shares Aquestive Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107 M | 86.7 M | 61.3 M | 48.7 M | 38.1 M | 33.8 M | 25.4 M | 20.7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 107 M | 20.7 M | 52.7 M |
Quarterly Shares Aquestive Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111 M | 99.3 M | 91.4 M | 91.1 M | 90.9 M | 73.6 M | 68.5 M | 64.7 M | 57.4 M | 55.6 M | 54.8 M | 53.4 M | 45.5 M | 41.5 M | 41.2 M | 39.2 M | 37.1 M | 35.6 M | 34.6 M | 33.6 M | 33.6 M | 33.6 M | 33.6 M | 25 M | 25 M | 25 M | 25 M | 23.6 M | 19.2 M | 15.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 111 M | 15.1 M | 49.3 M |
Shares of other stocks in the Biotechnology industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
9.88 M | $ 8.51 | 6.44 % | $ 84.1 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
2.41 B | $ 3.63 | -2.42 % | $ 8.73 B |  Australia |
 |
I-Mab
IMAB
|
220 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
15.3 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
84.2 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioNTech SE
BNTX
|
244 M | $ 97.45 | 2.04 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
46.7 M | $ 20.73 | 1.74 % | $ 969 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
257 M | $ 1.42 | 1.42 % | $ 365 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
86.8 M | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.65 M | $ 2.91 | -0.34 % | $ 4.79 M |  Israel |
 |
Aravive
ARAV
|
36.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
127 M | $ 23.99 | -0.91 % | $ 3.05 B | USA |
 |
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
66.4 M | $ 32.25 | 0.03 % | $ 2.14 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
266 M | $ 1.48 | -1.01 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
6.35 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
44.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
6.28 M | $ 2.58 | 1.12 % | $ 16.2 M | USA |
 |
AstraZeneca PLC
AZN
|
1.42 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
9.27 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.42 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
67.3 B | $ 3.79 | -0.98 % | $ 255 B | Britain |
 |
Allena Pharmaceuticals
ALNA
|
68 M | - | 3.16 % | $ 1.9 M | USA |
 |
Baudax Bio
BXRX
|
332 K | - | 0.59 % | $ 63 K | USA |
 |
Cabaletta Bio
CABA
|
100 M | $ 3.19 | 1.76 % | $ 321 M | USA |
 |
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | USA |
 |
CymaBay Therapeutics
CBAY
|
106 M | - | - | $ 3.45 B | USA |
 |
Aileron Therapeutics
ALRN
|
25.4 M | - | 10.36 % | $ 9.8 M | USA |